Axogen $200 million acquisition adds NerveTape to portfolio
Axogen, Inc. is acquiring BioCircuit for $200 million, bringing NerveTape—a high-growth, FDA-approved nerve repair device—into the portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.